{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:29:04Z","timestamp":1791721744328,"version":"4.3.4"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical University of Warsaw"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Iron is the most abundant transition metal in the human body and an essential element required for growth and survival. Our understanding of the molecular control of iron metabolism has increased dramatically over the past 20\u00a0years due to the discovery of hepcidin, which regulates the uptake of dietary iron and its mobilization from macrophages and hepatic stores. Anemia and iron deficiency are common in chronic kidney disease. The pathogenesis of anemia of chronic kidney disease is multifactorial. Correction of anemia requires two main treatment strategies: increased stimulation of erythropoiesis, and maintenance of an adequate iron supply to the bone marrow. However, there are still many uncertainties in regard to iron metabolism in patients with chronic kidney disease and in renal replacement therapy. The aim of this review was to summarize the current knowledge on iron metabolism in this population, including new biomarkers of iron status. There is an area of uncertainty regarding diagnostic utility of both erythroferrone (ERFE) and hepcidin in end-stage renal disease (ESRD) patients. Higher concentration of hepcidin in oligoanuric patients may reflect decreased renal clearance. Furthermore, the hepcidin-lowering effect of ERFE in ESRD patients treated with erythropoiesis-stimulating agents (ESAs) may be blunted by underlying inflammation and concomitant iron treatment. Thus, future studies should validate the use of ERFE as a biomarker of erythropoiesis and predictor of response to iron and ESA therapy in dialysis-dependent patients.<\/jats:p>","DOI":"10.1007\/s11255-020-02663-z","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T01:03:11Z","timestamp":1602032591000},"page":"935-944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Biomarkers of iron metabolism in chronic kidney disease"],"prefix":"10.1007","volume":"53","author":[{"given":"Glogowski","family":"Tomasz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojtaszek","family":"Ewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8701-8171","authenticated-orcid":false,"given":"Malyszko","family":"Jolanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"2663_CR1","unstructured":"Blanc B, Finch CA, Hallberg L, Herbert V, Lawkowicz W, Layrisse M, Mollin DL, Rachmilewitz M, Ramalingaswami V, Sanchez-Medal L, Vintrobe MM (1968) Nutritional anemias. Report of a WHO Scientific Group. WHO Tech Rep Ser 405:1\u201340. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/40707\/WHO_TRS_405.pdf;jsessionid=723826504327390B6E2BACE6A264BC23?sequence=1"},{"issue":"12","key":"2663_CR2","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/archinte.162.12.1401","volume":"162","author":"BC Astor","year":"2002","unstructured":"Astor BC, Muntner P, Levin A, Eustace JA, Coresh J (2002) Association of kidney function with anemia, the Third National Health and Nutrition Examination Survey (1988\u20131994). Arch Intern Med 162(12):1401\u20131408","journal-title":"Arch Intern Med"},{"issue":"7","key":"2663_CR3","doi-asserted-by":"publisher","first-page":"e0236132","DOI":"10.1371\/journal.pone.0236132","volume":"15","author":"T Sofue","year":"2020","unstructured":"Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M, Maruyama S, Wada T, Terada Y, Yamagata K, Narita I, Yanagita M, Sugiyama H, Shigematsu T, Ito T, Tamura K, Isaka Y, Okada H, Tsuruya K, Yokoyama H, Nakashima N, Hiromi K, Ohe K, Okada M, Kashihara N (2020) Prevalence of anemia in patients with chronic kidney disease in Japan: a nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS ONE 15(7):e0236132. https:\/\/doi.org\/10.1371\/journal.pone.0236132","journal-title":"PLoS ONE"},{"issue":"10","key":"2663_CR4","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt JL, Lin HY (2012) Mechanisms of anemia in CKD. JASN 23(10):1631\u20131634. https:\/\/doi.org\/10.1681\/ASN.2011111078","journal-title":"JASN"},{"issue":"3","key":"2663_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","volume":"71","author":"S Fishbane","year":"2018","unstructured":"Fishbane S, Spinowitz B (2018) Update on anemia in ESRD and earlier Stages of CKD: core curriculum. Am J Kidney Dis 71(3):423\u2013435. https:\/\/doi.org\/10.1053\/j.ajkd.2017.09.026","journal-title":"Am J Kidney Dis"},{"key":"2663_CR6","unstructured":"Filipczyk L, Kr\u00f3l P, Wystrychowski A (2010) Hepcydyna\u2014hormon w\u0105trobowy kontroluj\u0105cy gospodark\u0119 \u017celaza. Forum Nefrologiczne 3(4):233\u2013242. https:\/\/journals.viamedica.pl\/forum_nefrologiczne\/article\/view\/10359"},{"key":"2663_CR7","unstructured":"Mazur G, Wr\u00f3bel T, Nosol J (2005) Rola hepcydyny w regulacji homeostazy \u017celaza. Acta Haematologica Polonica 36(2):167\u2013175. https:\/\/pthit.pl\/Acta_Haematologica_Polonica,Hepcydyna_Hemochromatoza_Niedokrwistosc_w_przebiegu_chorob_przewleklych,250.html"},{"issue":"2","key":"2663_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2007-12-077388","volume":"112","author":"NC Andrews","year":"2008","unstructured":"Andrews NC (2008) Forging a field: the golden age iron biology. Blood 112(2):219\u2013230. https:\/\/doi.org\/10.1182\/blood-2007-12-077388","journal-title":"Blood"},{"issue":"4","key":"2663_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1053\/j.seminhematol.2009.06.004","volume":"46","author":"C Beaumont","year":"2009","unstructured":"Beaumont C, Delaby C (2009) Recycling iron in normal and pathological states. Semin Hematol 46(4):328\u2013338. https:\/\/doi.org\/10.1053\/j.seminhematol.2009.06.004","journal-title":"Semin Hematol"},{"key":"2663_CR10","unstructured":"Lipi\u0144ski P, Starzy\u0144ski R (2004) Regulacja og\u00f3lnoustrojowej homeostazy \u017celaza przez hepcydyn\u0119.\u00a0Post\u0119py Hig Med Dosw (online) 58:65\u201373. https:\/\/www.phmd.pl\/api\/files\/view\/1702.pdf"},{"issue":"11","key":"2663_CR11","doi-asserted-by":"publisher","first-page":"7806","DOI":"10.1074\/jbc.m008922200","volume":"276","author":"CH Park","year":"2001","unstructured":"Park CH, Valore EV, Waring AJ, Ganz T (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276(11):7806\u20137810. https:\/\/doi.org\/10.1074\/jbc.m008922200","journal-title":"J Biol Chem"},{"key":"2663_CR12","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1056\/NEJMra1401038","volume":"372","author":"C Camaschella","year":"2015","unstructured":"Camaschella C (2015) Iron-deficiency anemia. N Engl J Med 372:1832\u20131843. https:\/\/doi.org\/10.1056\/NEJMra1401038","journal-title":"N Engl J Med"},{"key":"2663_CR13","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMra1004967","volume":"366","author":"RE Fleming","year":"2012","unstructured":"Fleming RE, Ponka P (2012) Iron overload in human disease. N Engl J Med 366:348\u2013359. https:\/\/doi.org\/10.1056\/NEJMra1004967","journal-title":"N Engl J Med"},{"issue":"16","key":"2663_CR14","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood-2017-11-737411","volume":"131","author":"C Casu","year":"2018","unstructured":"Casu C, Nemeth E, Rivella S (2018) Hepcidin agonists as therapeutic tools. Blood 131(16):1790\u20131794. https:\/\/doi.org\/10.1182\/blood-2017-11-737411","journal-title":"Blood"},{"key":"2663_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1182\/asheducation-2009.1.207","volume":"2009","author":"A-S Zhang","year":"2009","unstructured":"Zhang A-S, Enns CA (2009) Molecular mechanisms of normal iron homeostasis. Hematology Am Soc Hematol Educ Program 2009:207\u2013214. https:\/\/doi.org\/10.1182\/asheducation-2009.1.207","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2663_CR16","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.3324\/haematol.2017.181743","volume":"103","author":"MR Hanudel","year":"2018","unstructured":"Hanudel MR, Rappaport M, Chua K, Gabayan V, Qiao B, Jung G, Salusky IB, Ganz T, Nemeth E (2018) Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica 103(4):e141\u2013e142. https:\/\/doi.org\/10.3324\/haematol.2017.181743","journal-title":"Haematologica"},{"issue":"6","key":"2663_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/sdi.12719","volume":"31","author":"T Hasegawa","year":"2018","unstructured":"Hasegawa T, Koiwa F, Akizawa T (2018) Anemia in conventional hemodialysis: finding the optimal treatment balance. Semin Dial 31(6):599\u2013606. https:\/\/doi.org\/10.1111\/sdi.12719","journal-title":"Semin Dial"},{"issue":"7","key":"2663_CR18","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1172\/jci31370","volume":"117","author":"C Peyssonnaux","year":"2007","unstructured":"Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, Johnson RS (2007) Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 117(7):1926\u20131932. https:\/\/doi.org\/10.1172\/jci31370","journal-title":"J Clin Invest"},{"issue":"9","key":"2663_CR19","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3390\/nu10091173","volume":"10","author":"N Ueda","year":"2018","unstructured":"Ueda N, Takasawa K (2018) Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease. Nutrients 10(9):1173. https:\/\/doi.org\/10.3390\/nu10091173","journal-title":"Nutrients"},{"issue":"10","key":"2663_CR20","doi-asserted-by":"publisher","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","volume":"152","author":"BD Parker","year":"2010","unstructured":"Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M et al (2010) The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 152(10):640\u2013648. https:\/\/doi.org\/10.7326\/0003-4819-152-10-201005180-00004","journal-title":"Ann Intern Med"},{"issue":"12","key":"2663_CR21","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.2215\/cjn.02160212","volume":"7","author":"AM Khan","year":"2012","unstructured":"Khan AM, Chirinos JA, Litt H, Yang W, Rosas SE (2012) FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Clin J Am Soc Nephrol 7(12):2017\u20132022. https:\/\/doi.org\/10.2215\/cjn.02160212","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"2663_CR22","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/jci46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121(11):4393\u20134408. https:\/\/doi.org\/10.1172\/jci46122","journal-title":"J Clin Invest"},{"issue":"7","key":"2663_CR23","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2215\/cjn.13281211","volume":"7","author":"MJ Mendoza","year":"2012","unstructured":"Mendoza MJ, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH et al (2012) Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol 7(7):1155\u20131162. https:\/\/doi.org\/10.2215\/cjn.13281211","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2663_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","volume":"23","author":"M Wolf","year":"2014","unstructured":"Wolf M, White KE (2014) Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 23(4):411\u2013419. https:\/\/doi.org\/10.1097\/01.mnh.0000447020.74593.6f","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"2663_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1687-9856-2012-27","volume":"2012","author":"V Braithwaite","year":"2012","unstructured":"Braithwaite V, Prentice AM, Doherty C, Prentice A (2012) FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study. Int J Pediatr Endocrinol 2012(1):27. https:\/\/doi.org\/10.1186\/1687-9856-2012-27","journal-title":"Int J Pediatr Endocrinol"},{"issue":"3","key":"2663_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s10157-012-0725-0","volume":"17","author":"SM Deger","year":"2013","unstructured":"Deger SM, Erten Y, Pasaoglu OT, Derici UB, Reis KA, Onec K, Pasaoglu H (2013) The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients. Clin Exp Nephrol 17(3):416\u2013423. https:\/\/doi.org\/10.1007\/s10157-012-0725-0","journal-title":"Clin Exp Nephrol"},{"issue":"7","key":"2663_CR27","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1182\/blood-2002-10-3235","volume":"101","author":"E Nemeth","year":"2003","unstructured":"Nemeth E, Valore E, Territo M, Schiller G, Lichtenstein A, Ganz T (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute phase protein. Blood 101(7):2461\u20132463. https:\/\/doi.org\/10.1182\/blood-2002-10-3235","journal-title":"Blood"},{"issue":"9","key":"2663_CR28","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1182\/blood-2006-06-027631","volume":"108","author":"DM Wrighting","year":"2006","unstructured":"Wrighting DM, Andrews NC (2006) Interleukin-6 induces hepcidin expression through STAT3. Blood 108(9):3204\u20133209. https:\/\/doi.org\/10.1182\/blood-2006-06-027631","journal-title":"Blood"},{"issue":"7","key":"2663_CR29","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1073\/pnas.072632499","volume":"99","author":"G Nicolas","year":"2002","unstructured":"Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, Sirito M, Sawadogo M, Kahn A, Vaulont S (2002) Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 99(7):4596\u20134601. https:\/\/doi.org\/10.1073\/pnas.072632499","journal-title":"Proc Natl Acad Sci USA"},{"key":"2663_CR30","unstructured":"Donderski R, Kardymowicz A, Manitius J (2009) Niedokrwisto\u015b\u0107 nerkopochodna. Wybrane aspekty diagnostyki i terapii. Choroby Serca i Naczy\u0144 6(2):82\u201393. https:\/\/journals.viamedica.pl\/choroby_serca_i_naczyn\/article\/view\/12052\/9930"},{"key":"2663_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.semnephrol.2016.02.001","volume":"36","author":"T Ganz","year":"2016","unstructured":"Ganz T, Nemeth E (2016) Iron balance and the role of hepcidin in chronic kidney disease. Semin Nephrol 36:87\u201393. https:\/\/doi.org\/10.1016\/j.semnephrol.2016.02.001","journal-title":"Semin Nephrol"},{"issue":"1","key":"2663_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12016-011-8291-x","volume":"42","author":"A Fasano","year":"2012","unstructured":"Fasano A (2012) Leaky gut and autoimmune diseases. Clin Rev Allergy Immunol 42(1):71\u201378. https:\/\/doi.org\/10.1007\/s12016-011-8291-x","journal-title":"Clin Rev Allergy Immunol"},{"issue":"10","key":"2663_CR33","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt JL, Lin HY (2012) Mechanism of anemia in CKD. J Am Soc Nephrol 23(10):1631\u20131634. https:\/\/doi.org\/10.1681\/ASN.2011111078","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 1","key":"2663_CR34","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1159\/000486968","volume":"1","author":"JB Wish","year":"2006","unstructured":"Wish JB (2006) Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1(suppl 1):S4\u2013S8. https:\/\/doi.org\/10.1159\/000486968","journal-title":"Clin J Am Soc Nephrol"},{"key":"2663_CR35","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0140-6736(15)60865-0","volume":"387","author":"A Lopez","year":"2016","unstructured":"Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L (2016) Iron deficiency anaemia. Lancet 387:907\u2013916. https:\/\/doi.org\/10.1016\/S0140-6736(15)60865-0","journal-title":"Lancet"},{"key":"2663_CR36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/kisup.2012.37","volume":"2","author":"The Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2012","unstructured":"The Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:279\u2013335. https:\/\/doi.org\/10.1038\/kisup.2012.37","journal-title":"Kidney Int Suppl"},{"issue":"5 Suppl 3","key":"2663_CR37","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1053\/j.ajkd.2006.03.010","volume":"47","author":"National Kidney Foundation","year":"2006","unstructured":"National Kidney Foundation (2006) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47(5 Suppl 3):S11\u2013S145. https:\/\/doi.org\/10.1053\/j.ajkd.2006.03.010","journal-title":"Am J Kidney Dis"},{"key":"2663_CR38","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/ndt\/gft033","volume":"28","author":"F Locatelli","year":"2013","unstructured":"Locatelli F, B\u00e1r\u00e1ny P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, H\u00f6rl W, London G, Vanholder R, Van Biesen W, ERA-EDTA ERBP Advisory Board (2013) Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 28:1346\u20131359. https:\/\/doi.org\/10.1093\/ndt\/gft033","journal-title":"Nephrol Dial Transplant"},{"key":"2663_CR39","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1744-9987.2010.00836.x","volume":"14","author":"Y Tsubakihara","year":"2010","unstructured":"Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T (2010) 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 14:240\u2013275. https:\/\/doi.org\/10.1111\/j.1744-9987.2010.00836.x","journal-title":"Ther Apher Dial"},{"key":"2663_CR40","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/nep.12139","volume":"18","author":"R Macginley","year":"2013","unstructured":"Macginley R, Walker R, Irving M (2013) KHA-CARI guideline: use of iron in chronic kidney disease patients. Nephrology (Carlton) 18:747\u2013749. https:\/\/doi.org\/10.1111\/nep.12139","journal-title":"Nephrology (Carlton)"},{"key":"2663_CR41","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1053\/j.ajkd.2009.10.043","volume":"55","author":"S Stancu","year":"2010","unstructured":"Stancu S, Stanciu A, Zugravu A, B\u00e2rsan L, Dumitru D, Lipan M, Mircescu G (2010) Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis 55:639\u2013647. https:\/\/doi.org\/10.1053\/j.ajkd.2009.10.043","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"2663_CR42","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1111\/hdi.12556","volume":"21","author":"AE Gaweda","year":"2017","unstructured":"Gaweda AE (2017) Markers of iron status in chronic kidney disease. Hemodial Int 21(Suppl 1):S21\u2013S27. https:\/\/doi.org\/10.1111\/hdi.12556","journal-title":"Hemodial Int"},{"issue":"Suppl 1","key":"2663_CR43","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.2215\/CJN.01490506","volume":"1","author":"JB Wish","year":"2006","unstructured":"Wish JB (2006) Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1(Suppl 1):S4\u2013S8. https:\/\/doi.org\/10.2215\/CJN.01490506","journal-title":"Clin J Am Soc Nephrol"},{"key":"2663_CR44","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nrneph.2010.139","volume":"6","author":"A Besarab","year":"2010","unstructured":"Besarab A, Coyne DW (2010) Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 6:699\u2013771. https:\/\/doi.org\/10.1038\/nrneph.2010.139","journal-title":"Nat Rev Nephrol"},{"key":"2663_CR45","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00467-018-3955-x","volume":"34","author":"M Hayes","year":"2019","unstructured":"Hayes M (2019) Measurement of iron status in chronic kidney disease. Pediatr Nephrol 34:605\u2013613. https:\/\/doi.org\/10.1007\/s00467-018-3955-x","journal-title":"Pediatr Nephrol"},{"key":"2663_CR46","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/ckj\/sfz091","volume":"13","author":"MMY Wong","year":"2019","unstructured":"Wong MMY, Tu C, Li Y, Pecoits-Filho R, Lopes AA, Narita I, Reichel H, Port FK, Sukul N, Stengel B, Robinson BM, Massy ZA, Pisoni RL, the CKDopps Investigators (2019) Anemia and iron deficiency among chronic kidney disease Stages 3\u20135ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kidney J 13:613\u2013624. https:\/\/doi.org\/10.1093\/ckj\/sfz091","journal-title":"Clin Kidney J"},{"key":"2663_CR47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2215\/CJN.01670408","volume":"4","author":"S Fishbane","year":"2009","unstructured":"Fishbane S, Pollack S, Feldman HI, Joffe MM (2009) Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988\u20132004. Clin J Am Soc Nephrol 4:57\u201361. https:\/\/doi.org\/10.2215\/CJN.01670408","journal-title":"Clin J Am Soc Nephrol"},{"key":"2663_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa048","author":"A Besarab","year":"2020","unstructured":"Besarab A, Drueke TB (2020) The problem with trasferrin saturation as an indicator of iron \u201csufficiency\u201d in chronic kidney disease. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaa048","journal-title":"Nephrol Dial Transplant"},{"key":"2663_CR49","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/ndt\/gfw012","volume":"32","author":"T Kim","year":"2017","unstructured":"Kim T, Rhee CM, Streja E, Obi Y, Brunelli SM, Kovesdy CP, Kalantar-Zadeh K (2017) Longitudinal trends in serum ferritin levels and associated factors in a national incident hemodialysis cohort. Nephrol Dial Transplant 32:370\u2013377. https:\/\/doi.org\/10.1093\/ndt\/gfw012","journal-title":"Nephrol Dial Transplant"},{"key":"2663_CR50","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/ndt\/gfg493","volume":"19","author":"K Kalantar-Zadeh","year":"2004","unstructured":"Kalantar-Zadeh K, Rodriguez RA, Humphreys MH (2004) Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Naphrol Dial Transplant 19:141\u2013149. https:\/\/doi.org\/10.1093\/ndt\/gfg493","journal-title":"Naphrol Dial Transplant"},{"key":"2663_CR51","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1093\/ndt\/gfr044","volume":"26","author":"L Ruiz-Jaramillo Mde","year":"2011","unstructured":"Ruiz-Jaramillo Mde L, Guizar-Mendoza JM, Amador-Licona N, de Jesus G-N, Hern\u00e1ndez-Gonz\u00e1lez MA, Dubey-Ortega LA, Solorio-Meza SE (2011) Iron overload as cardiovascular risk factor in children and adolescents with renal disease. Nephrol Dial Transplant 26:3268\u20133273. https:\/\/doi.org\/10.1093\/ndt\/gfr044","journal-title":"Nephrol Dial Transplant"},{"key":"2663_CR52","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","volume":"29","author":"IC Macdougall","year":"2014","unstructured":"Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Cushway T, Roger SD, FIND-CKD Study Investigators (2014) FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 29:2075\u20132084. https:\/\/doi.org\/10.1093\/ndt\/gfu201","journal-title":"Nephrol Dial Transplant"},{"key":"2663_CR53","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5414\/cn109198","volume":"88","author":"IC Macdougall","year":"2017","unstructured":"Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Meier Y, Larroque S, Perrin A, Roger SD (2017) Erythropoietic response to oral iron in patients with non-dialysis-dependent chronic kidney disease in FIND-CKD trial. Clin Nephrol 88:301\u2013310. https:\/\/doi.org\/10.5414\/cn109198","journal-title":"Clin Nephrol"},{"key":"2663_CR54","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/nu10040428","volume":"10","author":"K Takasawa","year":"2018","unstructured":"Takasawa K, Takeda C, Wada T, Ueda N (2018) Optimal serum ferritin levels for iron deficiency anemia during oral iron therapy (OIT) in Japanese hemodialysis patients with minor inflammation and benefit of intravenous iron therapy for OIT-nonresponders. Nutrients 10:428. https:\/\/doi.org\/10.3390\/nu10040428","journal-title":"Nutrients"},{"key":"2663_CR55","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/sj.ki.5002223","volume":"71","author":"AK Singh","year":"2007","unstructured":"Singh AK, Coyne DW, Shapiro W, Rizkala AR, the DRIVE Study Group (2007) Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 71:1163\u20131171. https:\/\/doi.org\/10.1038\/sj.ki.5002223","journal-title":"Kidney Int"},{"key":"2663_CR56","doi-asserted-by":"publisher","first-page":"361","DOI":"10.5455\/medarh.2013.67.361-364","volume":"67","author":"A Musanovic","year":"2013","unstructured":"Musanovic A, Trnacevic S, Mekic M, Musanovic A (2013) The influence of inflammatory markers and CRP predictive value in relation to target hemoglobin level in patients on chronic hemodialysis. Med Arch 67:361\u2013364. https:\/\/doi.org\/10.5455\/medarh.2013.67.361-364","journal-title":"Med Arch"},{"key":"2663_CR57","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1093\/ndt\/gfq321","volume":"25","author":"N Tessitore","year":"2010","unstructured":"Tessitore N, Girelli D, Campostrini N, Bedogna V, Solero GP, Castagna A, Melilli E, Mantovani W, De Matteis G, Olivieri O, Poli A, Lupo A (2010) Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 25:3996\u20134002. https:\/\/doi.org\/10.1093\/ndt\/gfq321","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 6","key":"2663_CR58","doi-asserted-by":"publisher","first-page":"1626S","DOI":"10.3945\/ajcn.117.155937","volume":"106","author":"PS Suchdev","year":"2017","unstructured":"Suchdev PS, Williams AM, Mei Z, Flores-Ayala R, Pasricha SR, Rogers LM, Ml NS (1633S) Assessment of iron status in settings of inflammation: challenges and potential approaches. Am J Clin Nutr 106(Suppl 6):1626S\u20131633S. https:\/\/doi.org\/10.3945\/ajcn.117.155937","journal-title":"Am J Clin Nutr"},{"key":"2663_CR59","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ndt\/17.6.1063","volume":"17","author":"DC Tarng","year":"2002","unstructured":"Tarng DC, Huang TP (2002) Determinants of circulating soluble transferrin receptor level in chronic haemodialysis patients. Nephrol Dial Transplant 17:1063\u20131069. https:\/\/doi.org\/10.1093\/ndt\/17.6.1063","journal-title":"Nephrol Dial Transplant"},{"key":"2663_CR60","doi-asserted-by":"publisher","first-page":"363","DOI":"10.5414\/cnp58363","volume":"58","author":"WC Chiang","year":"2002","unstructured":"Chiang WC, Tsai TJ, Chen YM, Lin SL, Hsieh BS (2002) Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. Clin Nephrol 58:363\u2013369. https:\/\/doi.org\/10.5414\/cnp58363","journal-title":"Clin Nephrol"},{"key":"2663_CR61","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1053\/j.ajkd.2006.02.180","volume":"47","author":"YC Chen","year":"2006","unstructured":"Chen YC, Hung SC, Tarng DC (2006) Association between transferrin receptor\u2014ferritin index and conventional measures of iron responsiveness in hemodialysis patients. Am Kidney Dis 47:1036\u20131044. https:\/\/doi.org\/10.1053\/j.ajkd.2006.02.180","journal-title":"Am Kidney Dis"},{"key":"2663_CR62","first-page":"107","volume":"17","author":"CM Hackeng","year":"2004","unstructured":"Hackeng CM, Beerenhout CM, Hermans M, Van der Kuy PHM, Van der Dussen H, Van Dieijen-Visser MP, Hamuly\u00e1k K, Van der Sande FM, Leunissen KM, Koomanal JP (2004) The relationship between reticulocyte hemoglobin content with C-reactive protein and conventional iron parameters in dialysis patients. J Nephrol 17:107\u2013111","journal-title":"J Nephrol"},{"key":"2663_CR63","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1046\/j.1523-1755.1999.00627.x","volume":"56","author":"C Bovy","year":"1999","unstructured":"Bovy C, Tsobo C, Crapanzano L, Rorive G, Beguin Y, Albert A, Paulus JM (1999) Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Kidney Int 56:1113\u20131119. https:\/\/doi.org\/10.1046\/j.1523-1755.1999.00627.x","journal-title":"Kidney Int"},{"key":"2663_CR64","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/ndt\/16.7.1416","volume":"16","author":"N Tessitore","year":"2001","unstructured":"Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, Gammaro L, Brocco G, Restivo G, Bernich P, Lupo A, Maschio G (2001) The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16:1416\u20131423. https:\/\/doi.org\/10.1093\/ndt\/16.7.1416","journal-title":"Nephrol Dial Transplant"},{"key":"2663_CR65","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1053\/j.ajkd.2015.11.012","volume":"67","author":"LE Ratcliffe","year":"2016","unstructured":"Ratcliffe LE, Thomas W, Glen J, Padhi S, Pordes BAJ, Wonderling D, Connell R, Stephens S, Mikhail AI, Fogarty DG, Cooper JK, Dring B, Devonald MAJ, Brown C, Thomas ME (2016) Diagnosis and management of iron deficiency in CKD: a summary of the NICE guideline recommendations and their rationale. Am J Kidney Dis 67:548\u2013558. https:\/\/doi.org\/10.1053\/j.ajkd.2015.11.012","journal-title":"Am J Kidney Dis"},{"key":"2663_CR66","unstructured":"Chung M, Moorthy D, Hadar N, Salvi P, Iovin RC, Lau J (2012) Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease. Agency for Healthcare Research and Quality, Rockville. Report No.: 12(13)-EHC140-EF"},{"key":"2663_CR67","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2215\/CJN.05931108","volume":"4","author":"J Zaritsky","year":"2009","unstructured":"Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB (2009) Hepcidin\u2014a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 4:1051\u20131056. https:\/\/doi.org\/10.2215\/CJN.05931108","journal-title":"Clin J Am Soc Nephrol"},{"key":"2663_CR68","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3109\/08860220903216071","volume":"31","author":"J Malyszko","year":"2009","unstructured":"Malyszko J, Malyszko JS, Kozminski P, Mysliwiec M (2009) Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin. Ren Fail 31:876\u2013883. https:\/\/doi.org\/10.3109\/08860220903216071","journal-title":"Ren Fail"},{"key":"2663_CR69","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.2215\/CJN.08161109","volume":"5","author":"J Zaritsky","year":"2010","unstructured":"Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB (2010) Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 5:1010\u20131014. https:\/\/doi.org\/10.2215\/CJN.08161109","journal-title":"Clin J Am Soc Nephrol"},{"key":"2663_CR70","doi-asserted-by":"publisher","first-page":"e39783","DOI":"10.1371\/journal.pone.0039783","volume":"7","author":"NC van der Weerd","year":"2012","unstructured":"van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, Den Hoedt CH, Mazairac Albert HA, Nub\u00e9 MJ, Lars Penne E, Gaillard CA, Wetzels JFM, Wiegerinck ET, Swinkels DW, Blankestijn PJ, ter Wee PM, CONTRAST investigator (2012) Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS ONE 7:e39783. https:\/\/doi.org\/10.1371\/journal.pone.0039783","journal-title":"PLoS ONE"},{"key":"2663_CR71","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/ki.2009.21","volume":"75","author":"DR Ashby","year":"2009","unstructured":"Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, Maxwell PH, Choi P (2009) Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75:976\u2013981. https:\/\/doi.org\/10.1038\/ki.2009.21","journal-title":"Kidney Int"},{"key":"2663_CR72","doi-asserted-by":"publisher","first-page":"e99781","DOI":"10.1371\/journal.pone.0099781","volume":"9","author":"L Mercadal","year":"2014","unstructured":"Mercadal L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, Vrtovsnik F, Houillier P, Froissart M, Stengel B (2014) The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS ONE 9:e99781. https:\/\/doi.org\/10.1371\/journal.pone.0099781","journal-title":"PLoS ONE"},{"key":"2663_CR73","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000368512","volume":"40","author":"E \u0141ukaszyk","year":"2015","unstructured":"\u0141ukaszyk E, \u0141ukaszyk M, Koc-\u017b\u00f3rawska E, Tobolczyk J, Bodzenta-\u0141ukaszyk A, Ma\u0142yszko J (2015) Iron status and inflammation in early stages of chronic kidney disease. Kidney Blood Press Res 40:366\u2013373. https:\/\/doi.org\/10.1159\/000368512","journal-title":"Kidney Blood Press Res"},{"key":"2663_CR74","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000109968","volume":"28","author":"A Kato","year":"2008","unstructured":"Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A (2008) Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 28:115\u2013121. https:\/\/doi.org\/10.1159\/000109968","journal-title":"Am J Nephrol"},{"key":"2663_CR75","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000336482","volume":"2","author":"BV Stef\u00e1nsson","year":"2012","unstructured":"Stef\u00e1nsson BV, Abramson M, Nilsson U, Haraldsson B (2012) Hemodiafiltration improve plasma 25-hepcidin levels: a prospective, randomized, blinded, cross-over study comparing hemodialysis and hemodiafiltration. Nephron Extra 2:55\u201365. https:\/\/doi.org\/10.1159\/000336482","journal-title":"Nephron Extra"},{"key":"2663_CR76","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/ki.2010.254","volume":"78","author":"BA Ford","year":"2010","unstructured":"Ford BA, Eby CS, Scott MG, Coyne Daniel W (2010) Intra-individual variability of serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int 78:769\u2013773. https:\/\/doi.org\/10.1038\/ki.2010.254","journal-title":"Kidney Int"},{"key":"2663_CR77","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1093\/ndt\/gfs164","volume":"27","author":"HP Peters","year":"2012","unstructured":"Peters HP, Rumjon A, Bansal SS, Laarakkers Coby MM, van den Brand JAJG, Sarafidis P, Musto R, Malyszko J, Swinkels DW, Wetzels JFM, Macdougall IC (2012) Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. Nephrol Dial Transplant 27:3923\u20133929. https:\/\/doi.org\/10.1093\/ndt\/gfs164","journal-title":"Nephrol Dial Transplant"},{"key":"2663_CR78","doi-asserted-by":"publisher","first-page":"e0157063","DOI":"10.1371\/journal.pone.0157063","volume":"11","author":"CA Gaillard","year":"2016","unstructured":"Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Bansal SS, Cronin M, Meier Y, Larroque S, Roger SD, Macdougall IC (2016) Hepcidin response to iron therapy in patients with non-dialysis dependent CKD: an analysis of the FIND-CKD trial. PLoS ONE 11:e0157063. https:\/\/doi.org\/10.1371\/journal.pone.0157063","journal-title":"PLoS ONE"},{"key":"2663_CR79","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.bcmd.2012.02.001","volume":"48","author":"A Finkenstedt","year":"2012","unstructured":"Finkenstedt A, Widschwendter A, Brasse-Lagnel CG, Theurl I, Hubalek M, Dieplinger H, Tselepis C, Ward DG, Vogel W, Zoller H (2012) Hepcidin is correlated to soluble hemojuvelin but not increased GDF15 during pregnancy. Blood Cells Mol Dis 48:233\u2013237. https:\/\/doi.org\/10.1016\/j.bcmd.2012.02.001","journal-title":"Blood Cells Mol Dis"},{"key":"2663_CR80","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s11255-011-0084-x","volume":"44","author":"J Malyszko","year":"2011","unstructured":"Malyszko J, Malyszko JS, Levin-Iaina N, Koc-Zorawska E, Kozminski P, Mysliwiec M (2011) Is hemojuvelin a possible new player in iron metabolism in hemodialysis patients? Int Urol Nephrol 44:1805\u20131811. https:\/\/doi.org\/10.1007\/s11255-011-0084-x","journal-title":"Int Urol Nephrol"},{"key":"2663_CR81","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000336528","volume":"35","author":"A Rumjon","year":"2012","unstructured":"Rumjon A, Sarafidis P, Brincat S, Musto R, Malyszko J, Bansal SS, Macdougall IC (2012) Serum hemojuvelin and hepcidin levels in chronic kidney disease. Am J Nephrol 35:295\u2013304. https:\/\/doi.org\/10.1159\/000336528","journal-title":"Am J Nephrol"},{"key":"2663_CR82","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1182\/blood-2005-05-1845","volume":"106","author":"L Lin","year":"2005","unstructured":"Lin L, Goldberg YP, Ganz T (2005) Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood 106:2884\u20132889. https:\/\/doi.org\/10.1182\/blood-2005-05-1845","journal-title":"Blood"},{"key":"2663_CR83","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1182\/blood-2007-07-100677","volume":"111","author":"L Silvestri","year":"2008","unstructured":"Silvestri L, Pagani A, Camaschella C (2008) Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 111:924\u2013931. https:\/\/doi.org\/10.1182\/blood-2007-07-100677","journal-title":"Blood"},{"key":"2663_CR84","doi-asserted-by":"publisher","first-page":"12547","DOI":"10.1074\/jbc.M608788200","volume":"282","author":"AS Zhang","year":"2007","unstructured":"Zhang AS, Anderson SA, Meyers KR, Hernandez C, Eisenstein RS, Enns CA (2007) Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. J Biol Chem 282:12547\u201312556. https:\/\/doi.org\/10.1074\/jbc.M608788200","journal-title":"J Biol Chem"},{"key":"2663_CR85","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1159\/000342519","volume":"36","author":"OM Guti\u0450rrez","year":"2012","unstructured":"Guti\u0450rrez OM, Sun CC, Chen W, Babitt JL, Lin HY (2012) Statement of concern about a commercial assay used to measure soluble hemojuvelin in humans. Am J Nephrol 36:332\u2013333. https:\/\/doi.org\/10.1159\/000342519","journal-title":"Am J Nephrol"},{"key":"2663_CR86","doi-asserted-by":"crossref","first-page":"537","DOI":"10.20452\/pamw.1458","volume":"122","author":"J Malyszko","year":"2012","unstructured":"Malyszko J, Koc-\u017b\u00f3rawska E, Levin-Iaina N, Ma\u0142yszko J, Ko\u017ami\u0144ski P, Kobus G, My\u015bliwiec M (2012) New parameters in iron metabolism and functional iron deficiency in patients on maintenance hemodialysis. Pol Arch Med Wewn 122:537\u2013542","journal-title":"Pol Arch Med Wewn"},{"key":"2663_CR87","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1182\/blood-2008-07-170431","volume":"113","author":"S Lakhal","year":"2009","unstructured":"Lakhal S, Talbot NP, Crosby A, Stoepker C, Townsend ARM, Robbins PA, Pugh CW, Ratcliffe PJ, Mole DR (2009) Regulation of growth differentiation factor 15 by intracellular iron. Blood 113:1555\u20131536. https:\/\/doi.org\/10.1182\/blood-2008-07-170431","journal-title":"Blood"},{"key":"2663_CR88","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1365-2141.2009.07961.x","volume":"148","author":"I Theurl","year":"2010","unstructured":"Theurl I, Finkelstedt A, Schroll A, Nairz M, Sonnweber T, Bellmann-Weiler R, Theurl M, Seifert M, Wroblewski VJ, Murphy AT, Witcher D, Zoller H, Weiss G (2010) Growth differentiation factor in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Br J Hematol 148:449\u2013455. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07961.x","journal-title":"Br J Hematol"},{"key":"2663_CR89","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/ndt\/gfr575","volume":"27","author":"SN Breit","year":"2012","unstructured":"Breit SN, Carrero JJ, Tsai VW, Yagoutifam N, Luo W, Kuffner T, Bauskin AR, Wu L, Jiang L, Barany P, Heimburger O, Murikami MA, Apple FS, Marquis CP, Macia L, Lin S, Sainsbury A, Herzog H, Law M, Stenvinkel P, Brown DA (2012) Macrophage inhibitory cytokine-1 (MIC-1\/GDF15) and mortality in end-stage renal disease. Nephrol Dial Transplant 27:70\u201375. https:\/\/doi.org\/10.1093\/ndt\/gfr575","journal-title":"Nephrol Dial Transplant"},{"key":"2663_CR90","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2215\/CJN.03530708","volume":"4","author":"D Bolignano","year":"2009","unstructured":"Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, Buemi M (2009) Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 4:337\u2013344. https:\/\/doi.org\/10.2215\/CJN.03530708","journal-title":"Clin J Am Soc Nephrol"},{"key":"2663_CR91","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000447649","volume":"136","author":"E Castillo-Rodriguez","year":"2017","unstructured":"Castillo-Rodriguez E, Fernandez-Prado R, Martin-Cleary C, Pizarro-S\u00e1nchez MS, Sanchez-Ni\u00f1o MD, Sanz AB, Fernandez-Fernandez B, Ortiz A (2017) Kidney injury marker 1 and neutrophil gelatinase-associated lipocalin in chronic kidney disease. Nephron 136:263\u2013267. https:\/\/doi.org\/10.1159\/000447649","journal-title":"Nephron"},{"key":"2663_CR92","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s10157-017-1409-6","volume":"22","author":"IY Kim","year":"2018","unstructured":"Kim IY, Kim JH, Lee DW, Lee SB, Rhee H, Song SH, Seong EY, Kwak IS (2018) Plasma neutrophil gelatinase-associated lipocalin is associated with iron status in anemic patients with predialysis chronic kidney disease. Clin Exp Nephrol 22:28\u201334. https:\/\/doi.org\/10.1007\/s10157-017-1409-6","journal-title":"Clin Exp Nephrol"},{"key":"2663_CR93","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/0886022X.2015.1107823","volume":"38","author":"E Avci Cicek","year":"2016","unstructured":"Avci Cicek E, Rota S, Dursun B, Cavalci E (2016) Evaluation of serum NGAL and hepcidin levels in chronic kidney disease patients. Ren Fail 38:35\u201339. https:\/\/doi.org\/10.3109\/0886022X.2015.1107823","journal-title":"Ren Fail"},{"key":"2663_CR94","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"issue":"10","key":"2663_CR95","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/ajh.24820","volume":"92","author":"MD Cappellini","year":"2017","unstructured":"Cappellini MD, Comin-Colet J, De Francisco A, Dignass A, Doehner W, Lam CS, Macdougall IC, Rogler G, Camaschella C, Kadir R, Kassebaum NJ, Spahn DR, Taher AT, Musallam KM, IRON CORE Group (2017) Iron deficiency across chronic inflammatory conditions: international expert opinion o definition, diagnosis and management. Am J Hematol 92(10):1068\u20131078. https:\/\/doi.org\/10.1002\/ajh.24820","journal-title":"Am J Hematol"},{"issue":"5","key":"2663_CR96","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/14728222.2019.1599358","volume":"23","author":"J Malyszko","year":"2019","unstructured":"Malyszko J, Malyszko JS, Matuszkiewicz-Rowinska J (2019) Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opin Ther Targets 23(5):407\u2013421. https:\/\/doi.org\/10.1080\/14728222.2019.1599358","journal-title":"Expert Opin Ther Targets"},{"issue":"2","key":"2663_CR97","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000486968","volume":"47","author":"JB Wish","year":"2018","unstructured":"Wish JB, Aronoff GR, Bacon BR, Brugnara C, Eckardt KU, Ganz T, Macdougall IC, N\u00fa\u00f1ez J, Perahia AJ, Wood JC (2018) Positive iron balance in chronic kidney disease: how much is too much and how to tell? Am J Nephrol 47(2):72\u201383. https:\/\/doi.org\/10.1159\/000486968","journal-title":"Am J Nephrol"},{"key":"2663_CR98","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa117","author":"T Nakanishi","year":"2020","unstructured":"Nakanishi T, Kuragano T (2020) Potential hazards of recent trends in liberal iron use for renal anemia. Clin Kidney J. https:\/\/doi.org\/10.1093\/ckj\/sfaa117","journal-title":"Clin Kidney J"},{"issue":"4","key":"2663_CR99","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1681\/ASN.2015091009","volume":"27","author":"CR Lenihan","year":"2016","unstructured":"Lenihan CR, Winkelmayer WC (2016) The dawning of a new day in CKD anemia care? J Am Soc Nephrol 27(4):968\u2013970. https:\/\/doi.org\/10.1681\/ASN.2015091009","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2663_CR100","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/1744-9987.13458","volume":"24","author":"A Bnaya","year":"2020","unstructured":"Bnaya A, Shavit L, Malyszko JS, Malyszko J, Slotki I (2020) Labile plasma iron levels in chronic hemodialysis patients treated by intravenous iron supplementation. Ther Apher Dial 24(4):416\u2013422. https:\/\/doi.org\/10.1111\/1744-9987.13458","journal-title":"Ther Apher Dial"},{"issue":"suppl 3","key":"2663_CR101","doi-asserted-by":"publisher","first-page":"iii35","DOI":"10.1093\/ndt\/gfy175","volume":"33","author":"G Cobo","year":"2018","unstructured":"Cobo G, Lindholm B, Stenvinkel P (2018) Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant 33(suppl 3):iii35\u2013iii40","journal-title":"Nephrol Dial Transplant"},{"key":"2663_CR102","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clinbiochem.2020.02.001","volume":"79","author":"S Appleby","year":"2020","unstructured":"Appleby S, Chew-Harris J, Troughton RW, Richards AM, Pemberton CJ (2020) Analytical and biological assessment of circulating human erythroferrone. Clin Biochem 79:41\u201347. https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.02.001","journal-title":"Clin Biochem"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02663-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-020-02663-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02663-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T16:15:29Z","timestamp":1723738529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-020-02663-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":102,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["2663"],"URL":"https:\/\/doi.org\/10.1007\/s11255-020-02663-z","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"11 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}